Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to compare unfractionated heparin (UFH) and bivalirudin in the performance and subsequent outcomes of Primary percutaneous coronary intervention. This will be a pragmatic trial. Interventional procedures will be performed to reflect current and evolving standards, including predominant radial access. All patients will be treated with routine oral anti-platelet therapy pre-procedure. GP IIb/IIIa inhibitors will be reserved for 'bail out' treatment only.


Clinical Trial Description

HEAT-PPCI is a single-centre prospective, dual-arm, open-label, randomised controlled trial comparing two antithrombotic agents in patients undergoing PPCI. All patients presenting to the PPCI service at Liverpool Heart and Chest Hospital will be assessed for trial eligibility. The patients will be allocated by randomisation in equal proportions to the two treatment groups receiving UFH (70 units/kg prior to the procedure) or bivalirudin (bolus of 0.75 mg/kg prior to the start of the intervention, followed by an infusion of 1.75 mg/kg per hour for the duration of the procedure).

Pre-Specified Subgroup Analyses

- Subgroup analyses looking at the impact of access site comparing radial versus femoral route

- Assessment of the outcomes in diabetic patients receiving oral hypoglycaemic or insulin therapy versus all other patients

- Comparing the outcomes in patients < or ≥ 75 years of age

- Type of p2y12 receptor inhibiting antiplatelet agent (Examples: clopidogrel, prasugrel, ticagrelor)

- Patients with impaired LV function versus normal LV function

- Patients managed with actual or attempted primary PCI versus no immediate PCI procedure attempted

PLATELET FUNCTION SUBSTUDY A substudy will be performed to assess indices of coagulation and platelet function studies comparing the impact of heparin or bivalirudin therapy on coagulation status at the end of the PPCI procedure. This study will be performed on all patients treated between the hours of 0800 and 1600, Monday to Friday. A single blood sample taken at the time of general blood sampling for routine clinical screening will be analysed. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01519518
Study type Interventional
Source Liverpool Heart and Chest Hospital NHS Foundation Trust
Contact
Status Completed
Phase Phase 4
Start date February 2012
Completion date December 2013

See also
  Status Clinical Trial Phase
Completed NCT00378352 - REVEAL: Reduction of Infarct Expansion and Ventricular Remodeling With Erythropoietin After Large Myocardial Infarction Phase 2
Completed NCT02835534 - The Efficacy and Safety of rhTNK-tPA in Comparison With Alteplase(Rt-PA) as Fibrinolytic Therapy of Acute STEMI Phase 4
Completed NCT01388504 - Nitrites in Acute Myocardial Infarction Phase 2/Phase 3
Completed NCT01878487 - Assessment of Lumen Expansion After Thrombus Extraction in Primary Percutaneous Coronary Intervention N/A
Recruiting NCT00284323 - Salvage: Postconditioning With Adenosine for STEMI Phase 2